• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

作者信息

Bex Axel, Albiges Laurence, Staehler Michael, Bensalah Karim, Giles Rachel H, Dabestani Saeed, Hofmann Fabian, Hora Milan, Kuczyk Markus A, Lam Thomas B, Marconi Lorenzo, Merseburger Axel S, Fernández-Pello Sergio, Tahbaz Rana, Abu-Ghanem Yasmin, Volpe Alessandro, Ljungberg Börje, Escudier Bernard, Powles Thomas

机构信息

Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

出版信息

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7.

DOI:10.1016/j.eururo.2018.08.029
PMID:30201510
Abstract
摘要

相似文献

1
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.欧洲泌尿外科学会肾癌指南小组与国际肾癌联盟联合声明：人用药品委员会对伊匹木单抗和纳武单抗用于肾癌的否决并不改变基于证据的指南推荐。
Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7.
2
Nivolumab plus ipilimumab in advanced renal-cell carcinoma.纳武利尤单抗联合伊匹木单抗治疗晚期肾细胞癌。
Lancet Oncol. 2018 May;19(5):e232. doi: 10.1016/S1470-2045(18)30257-2. Epub 2018 Mar 29.
3
First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.转移性肾细胞癌的一线系统治疗：系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):309-321. doi: 10.1016/j.eururo.2018.03.036. Epub 2018 Apr 13.
4
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.尼伏单抗联合伊匹单抗治疗乳头状肾细胞癌患者的疗效一般。
Jpn J Clin Oncol. 2021 Apr 1;51(4):646-653. doi: 10.1093/jjco/hyaa229.
5
[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].纳武利尤单抗联合伊匹木单抗对比舒尼替尼单药治疗——AUO的SUNNIFORECAST AN 41/16：一项针对既往未接受治疗的晚期（不可切除或转移性）非透明细胞肾细胞癌患者的2期随机开放标签研究
Urologe A. 2017 Jun;56(6):802-803. doi: 10.1007/s00120-017-0397-1.
6
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.一线纳武利尤单抗联合伊匹单抗与舒尼替尼治疗转移性肾细胞癌：成本效果分析。
JAMA Oncol. 2019 Apr 1;5(4):491-496. doi: 10.1001/jamaoncol.2018.7086.
7
Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.免疫检查点抑制剂相关性心肌炎：并非所有病例在临床上都很明显。
Eur Heart J. 2018 Oct 7;39(38):3553. doi: 10.1093/eurheartj/ehy485.
8
Updates to the Management of Kidney Cancer.肾癌的治疗进展。
J Natl Compr Canc Netw. 2018 May;16(5S):639-641. doi: 10.6004/jnccn.2018.0039.
9
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于既往未治疗的晚期肾细胞癌：CheckMate 214 研究中日本患者的分析结果，随访时间延长。
Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.
10
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.派姆单抗联合阿昔替尼与纳武利尤单抗联合伊匹单抗作为中高危晚期肾细胞癌的一线治疗：来自巴西私人视角的需要治疗人数分析。
J Med Econ. 2021 Jan-Dec;24(1):291-298. doi: 10.1080/13696998.2021.1883034.

引用本文的文献

1
Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.联合免疫检查点和 VEGFR 抑制治疗转移性肾细胞癌低危和老年患者。
Clin Genitourin Cancer. 2020 Jun;18(3):179-184.e3. doi: 10.1016/j.clgc.2019.11.016. Epub 2019 Dec 5.
2
Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab.纳武利尤单抗治疗晚期肾细胞癌患者的条件生存。
Med Sci Monit. 2019 Aug 30;25:6518-6522. doi: 10.12659/MSM.916984.